Compare Annaly Capital Management, Inc. (NLY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Novavax Inc — how do they compare? Annaly Capital Management, Inc. trades at $18.31 (market cap $13.77B), while Novavax Inc trades at $12.73 (market cap $1.82B). The key difference: Annaly Capital Management, Inc. is far larger — about 7.6× Novavax Inc's market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 91 Days and Novavax Inc for 59 Days on average.
| NLY | NVAX | |
|---|---|---|
Market Cap | $13.77B | $1.82B |
Volume | 21,283,879 | 6,198,505 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $12.56 |
52-Week Low | $17.93 | $6.22 |
Typical Hold Time | 91 Days | 59 Days |
Enterprise Value | $135.80B | $1.39B |
Dividend Yield | 16.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $18.30, up 2.06% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows strong profitability with a 92.77% net income margin and a low P/E of 4.41. Recent earnings have consistently beaten estimates, and the company maintains a high dividend yield near 15%, supported by a $0.75 quarterly payout announced for Q3 2026.
The outlook is mixed: attractive valuation and high yield offer upside potential, but significant cash flow volatility and rising debt-to-asset ratio pose risks. Analyst consensus is bullish with a $22.00 price target, yet technical weakness and interest rate sensitivity warrant caution for near-term performance.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
